Video
Author(s):
Arjun V. Balar, MD, discusses notable findings from 2 separate studies of pembrolizumab (Keytruda).
In this video, Arjun V. Balar, MD, shares notable findings from the ASCO 2021 abstracts “First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study” and “Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.” Balar is an associate professor of medicine at the NYU Grossman School of Medicine and genitourinary medical oncology program director at NYU Langone’s Perlmutter Cancer Center, New York.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.